yingweiwo

Levofloxacin [(-)-Ofloxacin]

Alias: (-)-Ofloxacin; Tavanic; Iquix; Fluoroquinolone; Levofloxacin; Levaquin; Quixin
Cat No.:V1411 Purity: ≥98%
Levofloxacin [(-)-Ofloxacin, Levaquin, Tavanic, Fluoroquinolone,Iquix, Quixin], a synthetic fluoroquinolone and the levo isomer of ofloxacin, is a broad-spectrum antibacterial drug approved for treating UTIs, RTIs etc.
Levofloxacin [(-)-Ofloxacin]
Levofloxacin [(-)-Ofloxacin] Chemical Structure CAS No.: 100986-85-4
Product category: Topoisomerase
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
500mg
1g
2g
5g
10g
50g
100g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Levofloxacin [(-)-Ofloxacin, Levaquin, Tavanic, Fluoroquinolone, Iquix, Quixin], a synthetic fluoroquinolone and the levo isomer of ofloxacin, is a broad-spectrum antibacterial drug approved for treating UTIs, RTIs etc. It inhibits DNA replication by blocking bacterial DNA gyrase's ability to supercoil. Levofloxacin is used to treat infections caused by bacteria in the stomach, urinary tract, respiratory system, and abdomen. With the exception of anaerobes, levofloxacin is only moderately active against the majority of aerobic Gram-positive and Gram-negative organisms.

Biological Activity I Assay Protocols (From Reference)
Targets
Quinolone; TOPO IV
ln Vitro

In vitro activity: Levofloxacin exhibits moderate activity against anaerobes and is active against the majority of aerobic Gram-positive and Gram-negative organisms.[1] Levofloxacin is 2- to 4-fold more active than ciprofloxacin against Staphylococcus aureus, Xanthomonas maltophilia, and Bacteroides fragilis, and two-fold more active than ciprofloxacin against Streptococcus pneumoniae. When it comes to killing coagulase-negative staphylococci and Acinetobacter species, levofloxacin is two to eight times more potent than ciprofloxacin; however, these differences in potency might not have any practical significance. 90% of streptococci are inhibited by levofloxacin at concentrations ranging from 1 mg to 2 mg/mL.[2] Levofloxacin shows bactericidal and inhibitory properties against extracellular or intracellular tubercle bacilli that are two times stronger than those of ofloxacin. [3] Levofloxacin, with a 50% inhibitory concentration of about 80 mg/mL at 48 and 72 hours, has the least inhibitory effect on osteoblastic cell growth. As shown by alizarin red staining and biochemical analysis on day 14, levofloxacin significantly inhibits calcium deposition.[4] In cultured rabbit chondrocytes, levofloxacin inhibits glycosaminoglycan synthesis first, DNA synthesis second, and mitochondrial function at actual arthropathic concentrations; however, these changes are reversible and do not result in the death of the cells.[5]

ln Vivo
Levofloxacin is equally as effective as ciprofloxacin, if not more so, in treating systemic infections in mice with pyelonephritis. Mice's serum and tissue contain greater concentrations of levofloxacin than ciprofloxacin.[2]
Animal Protocol
Matured male Albino mice
10.7 mg/kg
Intraperitoneal injection; 10.7 mg/kg, once daily for 10 days or 3 weeks.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Absorption of levofloxacin following oral administration is rapid and essentially complete, with an oral bioavailability of approximately 99%. Due to its nearly complete absorption, the intravenous and oral formulations of levofloxacin may be interchangeable. The Tmax is generally attained 1-2 hours following administration and the Cmax is proportional to the given dose - an intravenous dose of 500mg infused over 60 minutes resulted in a Cmax of 6.2 ± 1.0 µg/mL whereas a 750mg dose infused over 90 minutes resulted in a Cmax of 11.5 ± 4.0 µg/mL. Oral administration with food prolongs the Tmax by approximately 1 hour and slightly decreases the Cmax, but these changes are not likely to be clinically significant. Systemic absorption following oral inhalation is approximately 50% lower than that observed following oral administration.
The majority of administered levofloxacin is excreted unchanged in the urine. Following the administration of a single oral dose of levofloxacin, approximately 87% was eliminated unchanged in the urine within 48 hours and less than 4% was eliminated in the feces within 72 hours.
Levofloxacin is widely distributed in the body, with an average volume of distribution following oral administration between 1.09-1.26 L/kg (~89-112 L). Concentrations in many tissues and fluids may exceed those observed in plasma. Levofloxacin is known to penetrate well into skin tissue, fluids (e.g. blisters), lung tissue, and prostatic tissue, amongst others.
The average apparent total body clearance of levofloxacin ranges from 8.64-13.56 L/h, and its renal clearance ranges from 5.76-8.52 L/h. The relative similarity of these ranges indicates a small degree of non-renal clearance.
The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues and in blister fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the blister fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of levaquin, respectively, to healthy subjects. Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 ug/g over a 24-hour period after a single 500 mg oral dose.
Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The mean + or - SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 + or - 1.4 and 0.5 + or - 0.2 ug/mL after the 500 mg doses, and 8.6+ or - 1.9 and 1.1 + or - 0.4 ug/mL after the 750 mg doses, respectively. The mean + or - SD peak and trough plasma concentrations attained following multiple once-daily IV regimens were approximately 6.4 + or - 0.8 and 0.6 + or - 0.2 ug/mL after the 500 mg doses, and 12.1+ or - 4.1 and 1.3 + or - 0.71 ug/mL after the 750 mg doses, respectively. Oral administration of a 500 mg dose of levaquin with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration. Therefore, levaquin tablets can be administered without regard to food. It is recommended that levaquin oral solution be taken 1 hour before or 2 hours after eating.
Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of levofloxacin from a 500 mg tablet and a 750 mg tablet of Levaquin are both approximately 99%, demonstrating complete oral absorption of levofloxacin. Following a single intravenous dose of Levaquin to healthy volunteers, the mean + or - SD peak plasma concentration attained was 6.2 + or - 1.0 ug/mL after a 500 mg dose infused over 60 minutes and 11.5+ or - 4.0 ug/mL after a 750 mg dose infused over 90 minutes.
Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving levaquin.
For more Absorption, Distribution and Excretion (Complete) data for Levofloxacin (6 total), please visit the HSDB record page.
Metabolism / Metabolites
Only 2 metabolites, desmethyl-levofloxacin and levofloxacin-N-oxide, have been identified in humans, neither of which appears to carry any relevant pharmacological activity. Following oral administration, less than 5% of the administered dose was recovered in the urine as these metabolites, indicating very little metabolism of levofloxacin in humans. The specific enzymes responsible for the demethylation and oxidation of levofloxacin have yet to be ascertained.
Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity.
Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans. Levofloxacin is rapidly and essentially completely absorbed after oral administration. It is distributed into body tissues, especially in the skin and lung tissues. Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity. Levofloxacin is excreted largely as unchanged drug in the urine (L1009).
Route of Elimination: Mainly excreted as unchanged drug in the urine.
Half Life: 6-8 hours
Biological Half-Life
The average terminal elimination half-life of levofloxacin is 6-8 hours.
The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously.
The pharmacokinetics of oral levofloxacin and its penetration into inflammatory fluid were studied in 6 healthy male subjects (ages 18-45 yr) who received 500 mg drug every 12 hr for 5 doses or 500 mg every 24 hr for 3 doses in an open crossover design. ... Mean terminal elimination half-lives in plasma were 7.9 and 8 hr for the 2 regimens, respectively, and the same values were seen for inflammatory fluid. ...
After single oral administration of (14)C-levofloxacin at a dose of 20 mg kg(-1) under non-fasting conditions, the absorption, distribution and excretion of radioactivity were studied in albino and pigmented rats. ... The uveal tract concentrations reached the maximum value (C(max)) of 26.33 +/- 0.75 ug eq. g(-1) at 24 hr after dosing and declined slowly with a terminal half-life of 468.1 hr (19.5 days).
Toxicity/Toxicokinetics
Toxicity Summary
Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
Hepatotoxicity
In short term studies, levofloxacin has been associated with minor elevations in serum ALT and AST levels in 2% to 5% of patients. The abnormalities were usually asymptomatic and transient and rarely require dose modification. With its wide scale use, levofloxacin has been implicated in in at least 50 instances of clinically apparent liver injury mostly in isolated case reports. The clinical presentation and course are typical of the hepatotoxicity of other fluoroquinolones, and the injury is likely a class effect. The latency to onset is usually short (1 to 3 weeks) and the onset is often abrupt with a hepatocellular or mixed pattern of injury, jaundice and, in some instances, hepatic failure. Cholestatic hepatitis can also occur. Immunoallergic features such as fever, rash and eosinophilia are common, but not particularly prominent. Autoantibodies are rare. The liver injury is usually self-limited, but several cases of acute liver failure have been linked to fluoroquinolones as well as instances of prolonged jaundice, cholestasis and vanishing bile duct syndrome. Levofloxacin, like ciprofloxacin, has also been implicated hypersensitivity reactions including rare cases of Stevens Johnson syndrome and toxic epidermal necrolysis, which may be accompanied by liver injury. While liver injury from levofloxacin is rare, the fluoroquinolones collectively are among the most frequent causes of clinically apparent liver injury including fatal cases and cases of chronic liver injury and bile duct paucity.
Likelihood score: A (well established cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Levofloxacin is the S-enantiomer of the fluoroquinolone, ofloxacin. No information is available on the clinical use of levofloxacin during breastfeeding. However, amounts in breastmilk appear to be far lower than the infant dose and would not be expected to cause any adverse effects in breastfed infants. Fluoroquinolones such as levofloxacin have traditionally not been used in infants because of concern about adverse effects on the infants' developing joints. However, more recent studies indicate little risk. The calcium in milk might prevent absorption of the small amounts of fluoroquinolones in milk, but insufficient data exist to prove or disprove this assertion. Use of levofloxacin is acceptable in nursing mothers with monitoring of the infant for possible effects on the gastrointestinal flora, such as diarrhea or candidiasis (thrush, diaper rash). Avoiding breastfeeding for 4 to 6 hours after a dose should decrease the exposure of the infant to levofloxacin in breastmilk. Maternal use of an eye drop that contains levofloxacin presents negligible risk for the nursing infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
Levofloxacin is 24-38% protein-bound in plasma, primarily to albumin. The extent of protein-binding is independent of its plasma concentration.
Toxicity Data
LD50: 640 mg/kg (Oral, Rat)
Interactions
Warfarin: Potential pharmacologic interaction (increased prothrombin time). Monitor prothrombin time or other suitable coagulation tests and monitor for bleeding.
Theophylline: Pharmacokinetic interaction unlikely. However, pharmacokinetic interaction (increased theophylline half-life and increased risk of theophylline-related adverse effects) occurs with some other quinolones. Closely monitor serum theophylline concentrations and adjust theophylline dosage accordingly; consider that adverse theophylline effects (e.g., seizures) may occur with or without elevated theophylline concentrations.
Sucralfate: Potential pharmacokinetic interaction (decreased levofloxacin absorption); no pharmacokinetic interaction if given 2 hours apart. Administer levofloxacin at least 2 hours before or 2 hours after sucralfate.
Probenecid: Potential pharmacokinetic interaction (increased levofloxacin AUC and half-life). Not considered clinically important; dosage adjustments are not required.
For more Interactions (Complete) data for Levofloxacin (16 total), please visit the HSDB record page.
References

[1]. Drugs . 1994 Apr;47(4):677-700.

[2]. Antimicrob Agents Chemother . 1992 Apr;36(4):860-6.

[3]. Antimicrob Agents Chemother . 1994 May;38(5):1161-4.

[4]. J Orthop Res . 2000 Sep;18(5):721-7.

[5]. Antimicrob Agents Chemother . 1995 Sep;39(9):1979-83.

Additional Infomation
Therapeutic Uses
Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Nucleic Acid Synthesis Inhibitors
Levofloxacin is used for the treatment of acute bacterial sinusitis caused by susceptible Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis. /Included in US product label/
Levofloxacin is used for the treatment of community-acquired pneumonia caused by susceptible S. aureus (oxacillin-susceptible strains), S. pneumoniae (including penicillin-resistant strains (penicillin MIC of 2 ug/mL or greater)), H. influenzae, H. parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, M. catarrhalis, Chlamydophila pneumoniae (formerly Chlamydia pneumoniae), or Mycoplasma pneumoniae. /Included in US product label/
Levofloxacin is used for the treatment of mild to moderate complicated urinary tract infections caused by susceptible E. faecalis, Enterobacter cloacae, E. coli, K. pneumoniae, P. mirabilis, or Ps. aeruginosa and acute pyelonephritis caused by susceptible E. coli, including cases with concurrent bacteremia. /Included in US product label/
For more Therapeutic Uses (Complete) data for Levofloxacin (23 total), please visit the HSDB record page.
Drug Warnings
/BOXED WARNING/ WARNING: Fluoroquinolones, including Levaquin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
/BOXED WARNING/ WARNING: Fluoroquinolones, including Levaquin may exacerbate muscle weakness in persons with myasthenia gravis. Avoid Levaquin in patients with a known history of myasthenia gravis
Other serious and sometimes fatal events, some due to hypersensitivity, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including Levaquin. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following: fever, rash, or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson Syndrome); vasculitis; arthralgia; myalgia; serum sickness; allergic pneumonitis; interstitial nephritis; acute renal insufficiency or failure; hepatitis; jaundice; acute hepatic necrosis or failure; anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic abnormalities. The drug should be discontinued immediately at the first appearance of skin rash, jaundice, or any other sign of hypersensitivity and supportive measures instituted.
Post-marketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with Levaquin No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with hypersensitivity. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levaquin should be discontinued immediately if the patient develops signs and symptoms of hepatitis.
For more Drug Warnings (Complete) data for Levofloxacin (19 total), please visit the HSDB record page.
Pharmacodynamics
Levofloxacin is bactericidal and exerts its antimicrobial effects via inhibition of bacterial DNA replication. It has a relatively long duration of action in comparison with other antibiotics that allows for once or twice daily dosing. Levofloxacin is associated with QTc-interval prolongation and should be used with caution in patients with other risk factors for prolongation (e.g. hypokalemia, concomitant medications). Levofloxacin has demonstrated _in vitro_ activity against a number of aerobic gram-positive and gram-negative bacteria and may carry some activity against certain species of anaerobic bacteria and other pathogens such as _Chlamydia_ and _Legionella_. Resistance to levofloxacin may develop, and is generally due to mutations in DNA gyrase or topoisomerase IV, or via alterations to drug efflux. Cross-resistance may occur between levofloxacin and other fluoroquinolones, but is unlikely to develop between levofloxacin and other antibiotic classes (e.g. macrolides) due to significant differences in chemical structure and mechanism of action. As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C18H20FN3O4
Molecular Weight
361.37
Exact Mass
361.143
Elemental Analysis
C, 59.83; H, 5.58; F, 5.26; N, 11.63; O, 17.71
CAS #
100986-85-4
Related CAS #
138199-71-0; 177325-13-2;872606-49-0
PubChem CID
149096
Appearance
Off-white to light yellow solid powder
Density
1.5±0.1 g/cm3
Boiling Point
571.5±50.0 °C at 760 mmHg
Melting Point
218ºC
Flash Point
299.4±30.1 °C
Vapour Pressure
0.0±1.7 mmHg at 25°C
Index of Refraction
1.670
LogP
0.84
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
8
Rotatable Bond Count
2
Heavy Atom Count
26
Complexity
634
Defined Atom Stereocenter Count
1
SMILES
FC1C([H])=C2C(C(C(=O)O[H])=C([H])N3C2=C(C=1N1C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])OC([H])([H])[C@]3([H])C([H])([H])[H])=O
InChi Key
GSDSWSVVBLHKDQ-JTQLQIEISA-N
InChi Code
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
Chemical Name
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Synonyms
(-)-Ofloxacin; Tavanic; Iquix; Fluoroquinolone; Levofloxacin; Levaquin; Quixin
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 10~24 mg/mL (27.7~66.4 mM)
Water: ~11 mg/mL (~30.4 mM)
Ethanol: ~9 mg/mL (~24.9 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 1 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 1 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 1 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: 10 mg/mL (27.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.7672 mL 13.8362 mL 27.6725 mL
5 mM 0.5534 mL 2.7672 mL 5.5345 mL
10 mM 0.2767 mL 1.3836 mL 2.7672 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
CTID: NCT06568484
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-11-27
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
CTID: NCT06494072
Phase: Phase 4    Status: Recruiting
Date: 2024-11-20
The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment
CTID: NCT06684626
Phase: Phase 3    Status: Completed
Date: 2024-11-18
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort
CTID: NCT06649721
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-11-12
Early Antibiotics After Aspiration in ICU Patients
CTID: NCT05079620
Phase: Phase 4    Status: Terminated
Date: 2024-11-01
View More

Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention
CTID: NCT06017479
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-10-09


Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke
CTID: NCT05743101
Phase: N/A    Status: Not yet recruiting
Date: 2024-10-02
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke
CTID: NCT05799326
Phase: N/A    Status: Recruiting
Date: 2024-10-02
Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke
CTID: NCT05741905
Phase: N/A    Status: Recruiting
Date: 2024-10-02
Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults
CTID: NCT06616922
Phase: Phase 2    Status: Completed
Date: 2024-09-27
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
CTID: NCT03850379
Phase: Phase 2    Status: Completed
Date: 2024-09-19
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
CTID: NCT04502095
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-09-19
Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome
CTID: NCT05302531
Phase: Phase 1    Status: Recruiting
Date: 2024-08-29
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
CTID: NCT04062201
Phase: Phase 3    Status: Completed
Date: 2024-08-28
Evaluating Newly Approved Drugs for Multidrug-resistant TB
CTID: NCT02754765
Phase: Phase 3    Status: Completed
Date: 2024-07-24
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
CTID: NCT03511118
Phase:    Status: Recruiting
Date: 2024-07-24
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
CTID: NCT01270347
Phase: Phase 3    Status: Completed
Date: 2024-05-21
MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
CTID: NCT01180634
Phase: Phase 3    Status: Completed
Date: 2024-04-30
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
CTID: NCT03828201
Phase: Phase 2    Status: Recruiting
Date: 2024-04-12
Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study
CTID: NCT01353339
Phase: Phase 4    Status: Completed
Date: 2024-04-05
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort
CTID: NCT06081361
Phase: Phase 3    Status: Recruiting
Date: 2024-03-15
Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy
CTID: NCT06199778
Phase: N/A    Status: Terminated
Date: 2024-03-05
Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection
CTID: NCT06216639
Phase:    Status: Enrolling by invitation
Date: 2024-02-09
Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients
CTID: NCT02981615
Phase: Phase 3    Status: Completed
Date: 2023-11-27
Levofloxacin Concomitant Versus Levofloxacin Sequential
CTID: NCT06065267
Phase: Phase 4    Status: Not yet recruiting
Date: 2023-10-03
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
CTID: NCT02409290
Phase: Phase 3    Status: Completed
Date: 2023-09-28
D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy
CTID: NCT06049758
Phase: N/A    Status: Not yet recruiting
Date: 2023-09-22
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
CTID: NCT03474198
Phase: Phase 2/Phase 3    Status: Completed
Date: 2023-08-14
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
CTID: NCT01918397
Phase: Phase 2    Status: Completed
Date: 2023-05-24
Antibiotics to Decrease Post ERCP Cholangitis
CTID: NCT03087656
Phase: Phase 4    Status: Recruiting
Date: 2023-03-06
Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
CTID: NCT03551210
Phase: Phase 3    Status: Completed
Date: 2023-02-16
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
CTID: NCT05306223
Phase: Phase 4    Status: Recruiting
Date: 2023-01-18
Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection
CTID: NCT05393505
Phase: Phase 4    Status: Recruiting
Date: 2022-12-06
Healthy Patients & Effect of Antibiotics
CTID: NCT03098485
Phase: N/A    Status: Completed
Date: 2022-11-10
Bioequivalence Study of Levomerc 500 mg Tablets
CTID: NCT05339295
Phase: Phase 1    Status: Completed
Date: 2022-09-07
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
CTID: NCT05398679
Phase: Phase 4    Status: Not yet recruiting
Date: 2022-06-01
Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer
CTID: NCT00593567
Phase: Phase 2    Status: Completed
Date: 2022-05-31
Topical Antibiotics in Chronic Rhinosinusitis
CTID: NCT03673956
Phase: Phase 1/Phase 2    Status: Completed
Date: 2022-04-20
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
CTID: NCT04951986
Phase: Phase 3    Status: Recruiting
Date: 2022-03-31
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
CTID: NCT05250050
Phase: Phase 4    Status: Unknown status
Date: 2022-03-18
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
CTID: NCT01978938
Phase: Phase 3    Status: Completed
Date: 2022-01-11
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
CTID: NCT03032510
Phase: Phase 3    Status: Completed
Date: 2022-01-06
Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin
CTID: NCT05129176
Phase: Phase 4    Status: Unknown status
Date: 2021-11-24
Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
CTID: NCT04122287
Phase: Phase 4    Status: Unknown status
Date: 2021-11-18
The Treatment of Tuberculosis in HIV-Infected Patients
CTID: NCT00001033
Phase: Phase 3    Status: Completed
Date: 2021-11-04
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
CTID: NCT00000796
Phase: N/A    Status: Completed
Date: 2021-11-03
A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
CTID: NCT02205112
Phase: Phase 3    Status: Completed
Date: 2021-10-25
Helicobacter Pylori Eradication and Follow-up
CTID: NCT05061732
Phase: Phase 4    Status: Recruiting
Date: 2021-09-30
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
CTID: NCT02454205
Phase: Phase 2/Phase 3    Status: Completed
Date: 2021-09-29
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
CTID: NCT05023577
Phase: Phase 4    Status: Unknown status
Date: 2021-09-14
Short Compared With Standard Duration of Antibiotic Treatment for AECOPD
CTID: NCT03698682
Phase: Phase 2    Status: Completed
Date: 2021-07-16
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
CTID: NCT02701608
Phase: Phase 3    Status: Unknown status
Date: 2021-05-19
Prulifloxacin in Chronic Bacterial Prostatitis (CBP)
CTID: NCT03201796
Phase: Phase 2    Status: Completed
Date: 2021-05-13
Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study
CTID: NCT04639817
Phase:    Status: Completed
Date: 2021-04-28
Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations
CTID: NCT01988779
Phase: Phase 3    Status: Completed
Date: 2021-03-24
Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy
CTID: NCT04374188
Phase: N/A    Status: Unknown status
Date: 2021-03-03
Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer
CTID: NCT04204382
Phase: Phase 4    Status: Unknown status
Date: 2021-02-25
Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution
CTID: NCT03832465
Phase: Phase 4    Status: Completed
Date: 2021-02-05
Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.
CTID: NCT04107194
Phase: Phase 3    Status: Unknown status
Date: 2021-01-12
Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)
CTID: NCT03697993
Phase: Phase 4    Status: Terminated
Date: 2020-12-19
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
CTID: NCT01371656
Phase: Phase 3    Status: Completed
Date: 2020-12-07
LOAD VS Levofloxacine Concomitant
CTID: NCT04626193
Phase: Phase 4    Status: Unknown status
Date: 2020-11-12
Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD
CTID: NCT02067780
Phase: Phase 3    Status: Completed
Date: 2020-11-10
Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori
CTID: NCT04348786
Phase: Phase 4    Status: Completed
Date: 2020-09-16
Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease
CTID: NCT04432233
Phase: Phase 4    Status: Unknown status
Date: 2020-08-27
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
CTID: NCT03739528
Phase: Phase 3    Status: Completed
Date: 2020-08-18
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
CTID: NCT02024555
Phase: Phase 2    Status: Completed
Date: 2020-07-09
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
CTID: NCT03757234
Phase: Phase 2    Status: Completed
Date: 2020-07-07
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
CTID: NCT03740659
Phase: Phase 2    Status: Completed
Date: 2020-07-07
Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia
CTID: NCT04456712
Phase: Phase 4    Status: Completed
Date: 2020-07-02
Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia
CTID: NCT04352062
Phase: N/A    Status: Completed
Date: 2020-04-17
Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)
CTID: NCT04212403
Phase: N/A    Status: Completed
Date: 2020-02-24
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
CTID: NCT03159845
Phase: Phase 2    Status: Completed
Date: 2020-01-07
Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy
CTID: NCT03708848
Phase: Phase 4    Status: Completed
Date: 2019-12-10
The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy
CTID: NCT02789579
PhaseEarly Phase 1    Status: Unknown status
Date: 2019-10-01
-----
Assessment of the effects and tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v eye drops solution) for the treatment of bacterial conjunctivitis in adults: a multicentre, randomized, blinded-assessor, phase II non inferiority study – MIRAKLE
CTID: null
Phase: Phase 2    Status: Completed, Prematurely Ended
Date: 2021-06-02
Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to guide the treatment of periprosthetic joint infections; a prospective randomized clinical trial
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2020-11-17
ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS: AIR.
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2020-04-03
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2020-01-28
A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection
CTID: null
Phase: Phase 2, Phase 3    Status: Restarted, Completed
Date: 2019-06-26
A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults with Acute Pyelonephritis
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-09-04
An international, multicenter, randomized, blinded-assessor, parallel-group clinical study comparing eye drops of combined LEvofloxAcin + DExamethasone foR 7 days followed by dexamethasone alone for an additional 7 days vs. tobramycin + dexamethasone for 14 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults – LEADER 7.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2018-08-28
Aqueous humour concentrations after topical apPlication of combinEd levofloxacin dexamethasone eye dRops and of its single components: a randoMized, assEssor-blinded, parallel-group study in patients undergoing cataract
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-07-31
Efficiency of an antibioprophylaxy (levofloxacin) in patient treated by azacitidine
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2018-03-23
A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one anti-pseudomonal antibiotic versus two anti-pseudomonal antibiotics in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa.
CTID: null
Phase: Phase 3    Status: Ongoing, Prematurely Ended
Date: 2018-01-29
Acute appendicitis and microbiota- etiology and effects of the antimicrobial treatment
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2017-02-23
Antibiotic therapy vs. placebo in the treatment of acute uncomplicated appendicitis: a
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-12-27
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-12-15
Optimizing the antibiotic treatment of uncomplicated acute appendicitis: a prospective randomized multicenter study
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2016-03-03
Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (COVID-19)
CTID: null
Phase: Phase 4    Status: Trial now transitioned, Temporarily Halted, GB - no longer in EU/EEA, Ongoing
Date: 2015-09-16
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-02-24
Population pharmacokinetics of levofloxacin in intensive care patients with severe community-acquired pneumonia
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-11-07
Open-labeled, randomized, comparative clinical study of efficacy and safety of Levofloxan 0,5% eye drops in patients with Acute Bacterial Conjunctivitis.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-07-04
Efficacy of short duration sequential therapy versus standard intravenous therapy for patients with uncomplicated catheter related bacteremia due to S. aureus methicillin-susceptible.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-05-12
Prospective, Randomized, open label, European, multicenter study of the efficacy of the linezolid-rifampin combination versus standard of care in the treatment of Gram-positive prosthetic hip joint infection
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-10-08
Äkillistä välikorvatulehdusta sairastavan lapsen vuotavan putkikorvan hoito
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2012-06-14
Randomized open label clinical trial directed to optimize the duration of empirical antimicrobial therapy in haematologic patients with febrile neutropenia
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-03-26
Concomitant therapy with levofloxacyn versus sequential therapy with levofloxacin for eradication of H. pylori infection
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2012-02-07
Individualizing duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: a non-inferiority, randomized, controlled trial.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-12-20
Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-09-15
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-08-11
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2011-08-04
Ceftidoren versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis (AECB). Multi-centre, open-label, randomised, levofloxacin-controlled, parallel groups study, pilot study to evaluate the effects of the treatment on serum inflammatory biomarkers
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-06-27
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2011-05-24
Ensayo clínico prospectivo, aleatorizado, comparativo de la eficacia y seguridad del levofloxacino versus isoniazida en el tratamiento de la infección latente tuberculosa del trasplante hepático
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2011-03-03
Pharmacokinetic evaluation of fluoroquinolone antibiotics administered intravenously in intensive care patients with normal renal function and with renal hyperfiltration
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-04-22
treatment of healthcare-associated pneumonia: a prospective, multicenter study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2009-03-23
Estudio Comparativo de la Eficacia de Pautas “Cortas” y “Largas” de la Combinación Rifampicina-Levofloxacino en la Infección Estafilocócica Postquirúrgica Precoz y Hematógena de Prótesis Articular
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-03-12
A Randomized, Controlled, Open-Label Study to Investigate the Safety and Efficacy
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2008-12-16
Randomized, single-blind, parallel groups, controlled study to compare levofloxacin and prulifloxacin in patients with exacerbations of COPD previously treated with different antibiotics and admitted to Internal Medicine Departments
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-10-14
Durée de Traitement des Pyélonéphrites aiguës - Etude multicentrique, de non infériorité, randomisée évaluant deux durées de traitement antibiotique (5 versus 10 jours) dans les pyélonéphrites aiguës (PNA) communautaires non compliquées de la femme jeune. Etude DTP
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-10-06
Ensayo clínico unicéntrico, simple ciego y aleatorizado de comparación de la eficacia erradicadora de primera línea frente al Helicobacter pylori entre la triple terapia convencional oral con claritromicina, amoxicilina y omeprazol (CAO) durante 10 días frente a triple terapia alternativa oral con levofloxacino, amoxicilina y omeprazol (LAO) durante 10 días
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-09-29
A Randomized, Controlled, Open-Label Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge (Collatamp® G) Compared to Levofloxacin in Diabetic Patients with a Mild Infection of a Lower Extremity Skin Ulcer
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2008-09-11
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to
CTID: null
Phase: Phase 2    Status: Completed
Date: 2008-08-26
Farmacokinetische evaluatie van de eerste intraveneuze dosering van quinolones bij Intensieve Zorgen (IZ) patiënten met septische shock.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2008-08-20
Etude nationale, multicentrique, non comparative, évaluant l’efficacité de l’association lévofloxacine (500 mg) et rifampicine (600 ou 900 mg selon le poids) administrée une fois par jour par voie orale, en relais d’une antibiothérapie probabiliste par voie intraveineuse avec une durée totale de l’antibiothérapie de 6 semaines, dans le traitement des Infections sur Prothèses Ostéo-Articulaires (IPOA), avec changement de prothèse en deux temps
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-07-22
Pharmacokinetica of levofloxacine in bone
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-03-19
pharmacokinetic study by microdialysis of the distribution of ertapeneme and levofloxacine in infected foot ulcers of diabetics patients.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2007-12-11
Estudio Piloto Comparativo de Eficacia, Tolerancia y Seguridad de Moxifloxacino VO frente a Levofloxacino en Terapia Secuencial en Adultos Inmunocompetentes con Neumonía Adquirida en la Comunidad.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2007-11-23
Comparaison de deux durées (6 versus 12 semaines) de traitement antibiotique des ostéites du pied neuropathique chez le patient diabétique
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2007-05-10
Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with bacterial cholangitis. A double blind, randomiized study.
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2007-03-21
Prulifloxacin versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis AECB
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-02-15
A PILOT STUDY OF PRULIFLOXACIN VS. LEVOFLOXACIN IN PREVENTION OF POST-OPERATIVE URINARY BACTERIAL INFECTIONS IN PATIENTS UNDERGOING TURP
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2006-12-14
ENSAYO CLÍNICO ALEATORIZADO FASE IV PARA EVALUAR LA EFICACIA COMPARATIVA DEL TRATAMIENTO CON AMOXICILINA-CLAVULÁNICO O LEVOFLOXACINO EN PACIENTES CON NEUMONÍA ADQUIRIDA EN LA COMUNIDAD (NAC)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2006-11-23
PRULIFLOXACIN VERSUS LEVOFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL RHINOSINUSITIS ABRS
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-05-16
A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in elderly patients with serious community-acquired bacterial pneumonia treated with a short regimen fo ertapenem versus high-dose levofloxacin.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-01-07
A national, multicentric, randomised, controlled trial. Applications of a critical pathway using LEVOFLOXACIN for the management of patients with abnormal PSA
CTID: null
Phase: Phase 3    Status: Completed
Date: 2004-09-21
Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date:
A Phase II study of T-4288 in patients with community-acquired pneumonia
CTID: jRCT2080222672
Phase:    Status:
Date: 2014-11-27
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea
CTID: UMIN000015375
Phase:    Status: Complete: follow-up complete
Date: 2014-10-08
Effects of topical antibiotics after intravitreal injection of anti-vascular endothelial growth factor
CTID: UMIN000014964
Phase:    Status: Recruiting
Date: 2014-08-27
Factors related to dry eye after ocular surgery and its treatment.
CTID: UMIN000013501
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2014-03-26
Garenoxacin versus Levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology
CTID: UMIN000012421
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2013-11-28
Garenoxacilse if(down_display === 'none' || down_display === '') { icon_angle_up.style.display = 'none'; icon_angle_down.style.display

Contact Us